Pages that link to "Q422606"
Jump to navigation
Jump to search
The following pages link to didanosine (Q422606):
Displaying 50 items.
- HIV/AIDS (Q12199) (← links)
- ganciclovir (Q417640) (← links)
- ribavirin (Q421862) (← links)
- human immunodeficiency virus infectious disease (Q18556697) (← links)
- Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens (Q24799351) (← links)
- A prospective study of hearing changes after beginning zidovudine or didanosine in HIV-1 treatment-naïve people (Q25256661) (← links)
- tenofovir disoproxil (Q27132753) (← links)
- Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity (Q27650811) (← links)
- Bioretrosynthetic construction of a didanosine biosynthetic pathway (Q27682375) (← links)
- The effect of combinations of ampligen and zidovudine or dideoxyinosine against human immunodeficiency viruses in vitro (Q28319338) (← links)
- Synthesis and anti-HIV activity of isonucleosides (Q28320636) (← links)
- Optic neuritis associated with dideoxyinosine (Q28322509) (← links)
- Detection of human immunodeficiency virus type 1 clinical isolates with reduced sensitivity to zidovudine and dideoxyinosine by RNA.RNA hybridization (Q28323773) (← links)
- Anti-human immunodeficiency virus synergism by zidovudine (3'-azidothymidine) and didanosine (dideoxyinosine) contrasts with their additive inhibition of normal human marrow progenitor cells (Q28323830) (← links)
- Two-Drug Combinations of Zidovudine, Didanosine, and Recombinant Interferon- A Inhibit Replication of Zidovudine-Resistant Human Immunodeficiency Virus Type 1 Synergistically In Vitro (Q28324069) (← links)
- Exacerbation of dideoxycytidine-induced neuropathy with dideoxyinosine (Q28327056) (← links)
- Extended follow-up of peripheral neuropathy in patients with AIDS and AIDS-related complex treated with dideoxyinosine (Q28327344) (← links)
- Didanosine therapy in patients intolerant of or failing zidovudine therapy (Q28327854) (← links)
- Drug Points: pancreatitis associated with hydroxyurea in combination with didanosine (Q28345765) (← links)
- pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo (Q28368048) (← links)
- Relation of peripheral neuropathy to HIV treatment in four randomized clinical trials including didanosine (Q28371815) (← links)
- Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea (Q28373171) (← links)
- Excess peripheral neuropathy in patients treated with hydroxyurea plus didanosine and stavudine for HIV infection (Q28373174) (← links)
- Chloroquine exerts an additive in vitro anti-HIV type 1 effect when associated with didanosine and hydroxyurea (Q28373409) (← links)
- Safety and antiretroviral effects of combined didanosine and stavudine therapy in HIV-infected individuals with CD4 counts of 200 to 500 cells/mm3 (Q28374983) (← links)
- Once-daily administration of didanosine in combination with stavudine in antiretroviral-naive patients. The STADI Group (Q28374997) (← links)
- Hydroxyurea reduces the 50% inhibitory concentration of didanosine in HIV-infected cells (Q28375725) (← links)
- Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years (Q28379519) (← links)
- Centrosome amplification induced by the antiretroviral nucleoside reverse transcriptase inhibitors lamivudine, stavudine, and didanosine (Q28391510) (← links)
- High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen (Q28538692) (← links)
- Virologic and CD4 cell response to zidovudine or zidovudine and lamivudine following didanosine treatment of human immunodeficiency virus infection (Q31934105) (← links)
- Lack of an effect of azithromycin on the disposition of zidovudine and dideoxyinosine in HIV-infected patients (Q32039126) (← links)
- Determination of didanosine in maternal plasma, amniotic fluid, fetal and placental tissues by high-performance liquid chromatography-tandem mass spectrometry (Q33247013) (← links)
- Determination of abacavir, amprenavir, didanosine, efavirenz, nevirapine, and stavudine concentration in human plasma by MALDI-TOF/TOF. (Q33318736) (← links)
- Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastim in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma (Q33497699) (← links)
- Didanosine polymorphism in a supercritical antisolvent process (Q33510384) (← links)
- Oligonucleotide ligation assay for detecting mutations in the human immunodeficiency virus type 1 pol gene that are associated with resistance to zidovudine, didanosine, and lamivudine. (Q33657585) (← links)
- Relationship between didanosine exposure and surrogate marker response in human immunodeficiency virus-infected outpatients (Q33692547) (← links)
- Transplacental pharmacokinetics of dideoxyinosine in pigtailed macaques (Q33752846) (← links)
- Pharmacokinetics of dideoxyinosine in neonatal pigtailed macaques (Q33752888) (← links)
- Effect of antacids in didanosine tablet on bioavailability of isoniazid (Q33753738) (← links)
- Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients (Q33770032) (← links)
- Clinically relevant genotype interpretation of resistance to didanosine (Q33770146) (← links)
- Didanosine: an updated review of its use in HIV infection (Q33826219) (← links)
- Didanosine once daily: an overview (Q33866967) (← links)
- Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells (Q33900606) (← links)
- Zidovudine (AZT) versus AZT plus didanosine (ddI) versus AZT plus zalcitabine (ddC) in HIV infected adults (Q33910056) (← links)
- Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine (Q33953120) (← links)
- Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators (Q33975889) (← links)
- Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy (Q33979204) (← links)